| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11458091 | INDIVIOR | Compositions and methods for the treatment of opioid overdose |
Jul, 2038
(14 years from now) | |
Opvee is owned by Indivior.
Opvee contains Nalmefene Hydrochloride.
Opvee has a total of 1 drug patent out of which 0 drug patents have expired.
Opvee was authorised for market use on 22 May, 2023.
Opvee is available in spray;nasal dosage forms.
Opvee can be used as treating opioid overdose.
The generics of Opvee are possible to be released after 10 July, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | May 22, 2026 |
Drugs and Companies using NALMEFENE HYDROCHLORIDE ingredient
Market Authorisation Date: 22 May, 2023
Treatment: Treating opioid overdose
Dosage: SPRAY;NASAL
More Information on Dosage
OPVEE family patents
